To estimate the cost-effectiveness of an intervention to increase pneumococcal, influenza, and pertussis-containing vaccine uptake in adults aged 65 and older in primary care practices. DESIGN: Markov decision analysis model, comparing the cost-effectiveness of the 4 Pillars Practice Transformation Program with no intervention. SETTING: Diverse primary care practices in two U.S. cities. PARTICIPANTS: Clinical trial participants aged 65 and older. MEASUREMENTS: Quality-adjusted life years (QALYs), public health outcomes, and costs. Vaccination rates and intervention costs were derived from a randomized controlled cluster trial. Other parameters were derived from the medical literature and Centers for Disease Control and Prevention data. All parameters were individually and simultaneously varied over their distributions. RESULTS: With the intervention program and extrapolating over 10 years, there would be approximately 60,920 fewer influenza cases, 2,031 fewer pertussis cases, and 13,842 fewer pneumococcal illnesses in adults aged 65 and older. Total per-person vaccination and illness costs with the intervention were $23.93 higher than without the intervention, with a concurrent increase in effectiveness of 0.0031 QALYs, or $7,635 per QALY gained. In sensitivity analyses, no individual parameter variation caused the intervention to cost more than $50,000 per QALY gained. CONCLUSIONS: Implementing an intervention based on the 4 Pillars Practice Transformation Program is a costeffective undertaking in primary care practices for individuals aged 65 and older, with predicted public health benefits. J Am Geriatr Soc 65: 763-768, 2017. 
T he 4 Pillars Practice Transformation Program, also known as the 4 Pillars Toolkit (Toolkit), is a primary care practice improvement aid focused on changing behavior using evidence-based strategies 1,2 organized into four domains. The pillars are convenient vaccination services, communication with patients about the importance of immunization and the availability of vaccines, enhanced office systems to facilitate immunization, and motivation through an office immunization champion who monitors progress and encourages adherence to vaccination-promoting office procedures to improve vaccine uptake. 3 The Toolkit has been tested in several trials and found to be moderately effective at increasing immunization rates in adults 3, 4 and children. 5 The question remains whether the benefits of an intervention to improve adult vaccination rates are worth the effort of implementing a set of longterm patient, provider, and office system changes. From the provider's perspective, there is a financial incentive to increase vaccine uptake, because the Centers for Medicare and Medicaid Services has made reporting of influenza and pneumococcal vaccines a requirement for providers to avoid negative payment adjustments. 6 Moreover, in some states, administration fees adequately reimburse providers for offering adult vaccines. Conversely, there are costs associated with implementing some of the Toolkit strategies, such as educating and training staff, writing standing order protocols, establishing new policies, purchasing vaccine informational materials, and making or sending vaccination reminders.
The Toolkit is an online source of evidence-based practices for implementing a quality control project that contains background information on vaccines, case studies and best practices, strategies for making changes in each of the 4 Pillars' domains, resources, links to other reliable vaccination sites and a dashboard to assist practices with choosing strategies, mapping the change process, and tracking progress. The purpose of this study was to examine the cost-effectiveness of an intervention to increase pneumococcal vaccine uptake in adults aged 65 and older in primary care practices using the Toolkit. A Markov decision analysis model was used to estimate the cost-effectiveness of using the Toolkit to improve vaccination rates.
METHODS
Vaccination rates and intervention costs were derived from a randomized controlled cluster trial conducted in two U.S. cities (Pittsburgh and Houston) in diverse populations and medical practice settings. 4 The institutional review boards of the University of Pittsburgh, Baylor College of Medicine, and Harris Health System approved the trial.
The intervention using the Toolkit was designed to assist practices in improving uptake of influenza, pneumococcal, and tetanus-pertussis-diphtheria (Tdap) vaccines. Vaccination rates for each vaccine are based on those observed in the trial and improvements in rates after the intervention. 4 To simplify modeling procedures, it was assumed that the probability of receiving each vaccine was not correlated with the probability of receiving other vaccines. It was also assumed that the probabilities of receiving the two pneumococcal vaccines (23-valent pneumococcal polysaccharide vaccine (PPSV) and 13-valent pneumococcal conjugate vaccine (PCV13)) were equal. This assumption was tested in sensitivity analyses.
Vaccine effectiveness (VE) was used to determine protection from illness, with illness risk calculated as the illness attack rate for the population aged 65 and older multiplied by 1 minus VE. Influenza VE was based on medical literature and Centers for Disease Control and Prevention data and was varied widely to reflect recent trends in vaccine protection, [7] [8] [9] assuming yearly revaccination. Tdap VE considered only pertussis prevention, because of the rarity of tetanus and diphtheria, and was calculated as average pertussis VE over the 10-year-model time horizon using recent data on waning pertussis protection after vaccination. 10 Pneumococcal VE was similarly averaged, using waning parameters as a prior Delphi expert panel outlined adjusted for observed PCV13 effectiveness from a large randomized trial. 11, 12 Pneumococcal VE was then adjusted for the relative likelihood of disease due to each vaccine's serotypes, based on published reports of U.S. epidemiological surveillance data. 13 PPSV was assumed to prevent invasive pneumococcal disease from vaccine serotypes; PCV13 was assumed to prevent vaccineserotype invasive pneumococcal disease and nonbacteremic pneumococcal pneumonia.
U.S. databases and medical literature data [7] [8] [9] 14 describing vaccine costs and effectiveness, illness rates and costs, and quality-of-life utilities were used to inform base case parameter values and their ranges. The analysis took a societal perspective, following the reference case recommendations of the U.S. Panel on Cost Effectiveness in Health and Medicine. 15 The 4 Pillars intervention cost was estimated from questionnaire data obtained from intervention study sites regarding personnel and material costs to introduce and maintain the intervention. Improved vaccine uptake was that observed at the end of the 2-year trial. All model parameters are depicted in Table 1 .
A decision tree model was used to estimate the costeffectiveness of the Toolkit for improving vaccination rates in persons aged 65 and older ( Figure S1 ). Identical hypothetical cohorts were examined in the two modeled strategies. The sum of baseline vaccine uptake and observed percentage point improvement was held constant over the 10-year-model time horizon in the base case analysis. To account for illness-related loss of quality and duration of life, quality-adjusted life years (QALYs) lost because of illness was used as a measure of VE. Future costs and effectiveness were discounted at 3% per year.
To test the robustness of model results, all parameters were individually varied over the ranges listed in Table 1 . In addition, in a probabilistic sensitivity analysis, all parameters were simultaneously varied over distributions 3,000 times. Beta distributions approximating the listed ranges were assigned to probabilities and utilities; gamma distributions were used for costs and time lost because of illness.
RESULTS
Based on model results considering public health outcomes (Table 2) , improvements in vaccine uptake should lead to substantial decreases in illness frequency. Over the 10-year-model time horizon, influenza case incidence decreased 1.8 percentage points (PPs) (from 37.3% to 35.5% of the cohort), with comparable relative decreases in hospitalization and deaths due to influenza. Smaller decreases in pertussis illness (0.6 PPs), invasive pneumococcal disease (0.009 PPs), and nonbacteremic pneumococcal pneumonia (0.4 PPs) occurred. In 2014, there were 3,384,449 individuals aged 65 in the United States. With an intervention program in place and extrapolating over 10 years, there would be approximately 60,920 fewer influenza cases, 2,031 fewer pertussis cases, and 13,842 fewer pneumococcal illnesses in this age group.
In the cost-effectiveness analysis (Table 3) , total perperson vaccination and illness costs were $23.93 higher with the Toolkit intervention in place than with no program, with a concurrent increase in effectiveness of approximately 0.0031 fewer QALYs lost (~1.1 days). Thus, the Toolkit cost $7,635 per QALY gained.
In sensitivity analyses to test the robustness of these results, no individual parameter variation, as listed in Table 1 , caused the intervention to cost more than $50,000 per QALY gained. Variation of only two parameters caused the favored strategy to change when lowering the threshold to $20,000/QALY gained: (1) when the program-related absolute increase in influenza vaccination was below 1.7% (base case = 5%) or (2) when influenza VE was less than 28.1% (base case = 59.0%). Results were insensitive to individual variation of all other parameters over their listed ranges. For example, if the program cost is increased to the high end of its range, $2.26, from its base case value of $1.78 per eligible individual, the program will cost $8,980/QALY gained, and if the program cost is increased to $5 per person, the program will cost $16,656/QALY gained. In the base case analysis, it was assumed that individuals received both pneumococcal vaccines if they received any pneumococcal vaccination; if they received both only half the time, the intervention would cost, at most, $7,964/QALY gained. Conversely, varying three parameters in clinically plausible ranges (Figure S2) caused the intervention to become cost saving and more effective than no intervention: program-related increases in vaccination rates, influenza illness costs, and pneumococcal disease illness costs. Finally, in a probabilistic sensitivity analysis in which all parameters were simultaneously varied, the Toolkit intervention was cost saving in 13.8% of model iterations and favored in 95.1% at $50,000/QALY gained, a commonly cited cost-effectiveness benchmark. 16 
DISCUSSION
A cost-effectiveness analysis largely based on clinical trial data showed that an intervention designed to increase vaccination rates in adults cost $7,635 per QALY gained. In general, interventions costing less than $20,000 per QALY gained are considered "good buys," an investment in health improvement that is very reasonable to make. 17 In the literature and in the absence of U.S. cost-effectiveness criteria, benchmark values of $50,000 or $100,000 per QALY gained are often cited as economically reasonable in the United States. 16, 18 In addition, in sensitivity analyses, individual variation of model parameters within plausible ranges did not increase the Toolkit intervention cost to $50,000 or more per QALY gained, highlighting the robustness of the intervention's favorability. Plausible parameter variation could make the intervention less expensive and more effective than no intervention.
In prior work, the cost-effectiveness of hypothetical vaccination programs to increase influenza and pneumococcal vaccine uptake and decrease vaccination disparities in elderly minorities was explored. [19] [20] [21] These programs were found to be economically favorable in general but with higher costs per QALY gained than those found in the current analysis. Differences in modeled program costs, program-related improvements in vaccine uptake, and illnesses prevented were the main determinants of these higher costs per QALY. In prior work examining influenza and pneumococcal vaccines, 21 programs of varying intensity were estimated to cost from $2 to $17.84, much more than the current study's empirical cost of $1.78 (range $0.70-2.26), while modeling somewhat greater improvements in vaccine uptake than those observed in the 4 Pillars trial. In addition, the prior analyses modeled pneumococcal VE only against invasive pneumococcal disease and not against nonbacteremic pneumonia; protection against both infections was modeled in the present analysis.
Indirect (herd immunity) effects were not modeled in this analysis, a potential limitation. This choice is justified based on data suggesting that the indirect effect of vaccinating elderly adults is much less than that of vaccinating other age groups (e.g., children); thus, the relative indirect effect on the population of vaccinating elderly adults is smaller than for other groups, although if such effects were considered, it is likely that the cost-effectiveness of the Toolkit intervention for elderly adults would become even more favorable than the results reported here. The costs did not include the research personnel costs because these would not be included in a program using the Toolkit that the primary care practice initiated itself. In older adults, frailty could be an important predictor of influenza VE and influenza severity; frailty was not directly modeled, another limitation of the analysis.
Effectuating significant long-term changes in adult vaccination rates has been an elusive goal. Efforts to improve rates continue to be undertaken, but modest short-term improvements in vaccination uptake and limited reach of many programs raises the question, "Do the improvements in vaccination rates justify the effort required of the primary care practice?" This cost-effectiveness analysis offers a resounding "Yes" to that question. At an estimated cost per eligible individuals of $1.78 per year, few practices would not be able to implement an intervention using the 4 Pillars Practice Transformation Program.
Implementing an intervention based on the 4 Pillars Practice Transformation Program in an effort to increase vaccination of adults aged 65 and older would be costeffective in primary care practices. Even modest improvements in uptake can have a large effect on the health of these at-risk individuals.
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